JP7716992B2 - 骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用 - Google Patents

骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用

Info

Publication number
JP7716992B2
JP7716992B2 JP2021571942A JP2021571942A JP7716992B2 JP 7716992 B2 JP7716992 B2 JP 7716992B2 JP 2021571942 A JP2021571942 A JP 2021571942A JP 2021571942 A JP2021571942 A JP 2021571942A JP 7716992 B2 JP7716992 B2 JP 7716992B2
Authority
JP
Japan
Prior art keywords
cells
bone marrow
macrophages
antigen
marrow cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021571942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535550A (ja
JP2022535550A5 (cg-RX-API-DMAC7.html
Inventor
タティアナ アイ. ノボブラントセバ,
イゴール フェルドマン,
スティーブン エル. サジンスキー,
ジョゼフ エー. ウォール,
ブライアン オヌアライン,
ライアン フェニシー,
Original Assignee
ヴェルソー セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴェルソー セラピューティクス, インコーポレイテッド filed Critical ヴェルソー セラピューティクス, インコーポレイテッド
Publication of JP2022535550A publication Critical patent/JP2022535550A/ja
Publication of JP2022535550A5 publication Critical patent/JP2022535550A5/ja
Priority to JP2025107222A priority Critical patent/JP2025129213A/ja
Application granted granted Critical
Publication of JP7716992B2 publication Critical patent/JP7716992B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2021571942A 2019-06-04 2020-06-02 骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用 Active JP7716992B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025107222A JP2025129213A (ja) 2019-06-04 2025-06-25 骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962857169P 2019-06-04 2019-06-04
US62/857,169 2019-06-04
US201962867569P 2019-06-27 2019-06-27
US62/867,569 2019-06-27
US201962947948P 2019-12-13 2019-12-13
US62/947,948 2019-12-13
US202063032214P 2020-05-29 2020-05-29
US63/032,214 2020-05-29
PCT/US2020/035702 WO2020247371A1 (en) 2019-06-04 2020-06-02 Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025107222A Division JP2025129213A (ja) 2019-06-04 2025-06-25 骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用

Publications (3)

Publication Number Publication Date
JP2022535550A JP2022535550A (ja) 2022-08-09
JP2022535550A5 JP2022535550A5 (cg-RX-API-DMAC7.html) 2023-06-12
JP7716992B2 true JP7716992B2 (ja) 2025-08-01

Family

ID=73651973

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021571942A Active JP7716992B2 (ja) 2019-06-04 2020-06-02 骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用
JP2025107222A Pending JP2025129213A (ja) 2019-06-04 2025-06-25 骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025107222A Pending JP2025129213A (ja) 2019-06-04 2025-06-25 骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用

Country Status (11)

Country Link
US (1) US12552873B2 (cg-RX-API-DMAC7.html)
EP (1) EP3980463A4 (cg-RX-API-DMAC7.html)
JP (2) JP7716992B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220042055A (cg-RX-API-DMAC7.html)
CN (1) CN114401990A (cg-RX-API-DMAC7.html)
AU (1) AU2020288823A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021024242A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141334A1 (cg-RX-API-DMAC7.html)
IL (1) IL288510A (cg-RX-API-DMAC7.html)
TW (1) TW202110891A (cg-RX-API-DMAC7.html)
WO (1) WO2020247371A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
KR20220042055A (ko) 2019-06-04 2022-04-04 베르조 테라퓨틱스, 아이엔씨. 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도
GB2584664B (en) * 2019-06-10 2023-05-24 Newcells Biotech Ltd Improved retinal organoids and methods of making the same
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
US12682015B2 (en) * 2021-03-03 2026-07-14 International Business Machines Corporation Ensemble voting classifiers using adjusted thresholds
JP2024540484A (ja) * 2021-11-17 2024-10-31 アルトゥルバイオ, インコーポレイテッド 抗psgl-1抗体をjak阻害剤と組み合わせて使用してt細胞媒介性炎症性疾患またはがんを治療する方法
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒
CN120682308B (zh) * 2025-06-23 2025-12-02 北京昌盛鸿途生物科技有限公司 牛骨髓肽及其在提高免疫力中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033959A2 (en) 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
JP2007527393A (ja) 2003-06-30 2007-09-27 バイオ−テクノロジー・ジェネラル(イスラエル)リミテッド 特異的ヒト抗体
JP2007536933A (ja) 2004-05-10 2007-12-20 アブゲノミクス コーポレイション 抗体
JP2011524858A (ja) 2008-05-15 2011-09-08 セレクシーズ ファーマスーティカルズ コーポレーション 抗psgl−1抗体並びにその同定及び使用方法
JP2017524687A (ja) 2014-07-08 2017-08-31 サンフォード−バーナム メディカル リサーチ インスティテュート Psgl−1モジュレーターおよびその使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL362227A1 (en) 2000-03-24 2004-10-18 Genetic Institute, Llc A novel p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
CA2561835A1 (en) 2004-03-30 2005-10-13 Den Kgl. Veterinaer-Og Landbohojskole Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
WO2011143411A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy for traumatic brain injury
US20120130603A1 (en) 2010-11-18 2012-05-24 Sean Michael Simpson System and method for controlling a transmission of a human-powered vehicle
EP3222635A1 (en) * 2010-12-21 2017-09-27 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
EP2718325A4 (en) * 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
KR102061358B1 (ko) 2011-10-21 2019-12-31 트랜스진 에스.에이. 대식세포 활성화의 조절
WO2015077401A1 (en) 2013-11-20 2015-05-28 Drexel University Compositions and methods for macrophage conversion
WO2016033527A1 (en) 2014-08-29 2016-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic modulation by endocrine deprivation therapy improves sensitivity of tumor cells to immune mediated lysis
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
PE20190115A1 (es) 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso
GB201611535D0 (en) 2016-07-01 2016-08-17 King S College London Methods and compositions for treating cancer with siglec-9 activity modulators
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
WO2020006385A2 (en) 2018-06-29 2020-01-02 Verseau Therapeutics, Inc. Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
KR20220042055A (ko) 2019-06-04 2022-04-04 베르조 테라퓨틱스, 아이엔씨. 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527393A (ja) 2003-06-30 2007-09-27 バイオ−テクノロジー・ジェネラル(イスラエル)リミテッド 特異的ヒト抗体
JP2007536933A (ja) 2004-05-10 2007-12-20 アブゲノミクス コーポレイション 抗体
WO2007033959A2 (en) 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
JP2011524858A (ja) 2008-05-15 2011-09-08 セレクシーズ ファーマスーティカルズ コーポレーション 抗psgl−1抗体並びにその同定及び使用方法
JP2017524687A (ja) 2014-07-08 2017-08-31 サンフォード−バーナム メディカル リサーチ インスティテュート Psgl−1モジュレーターおよびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ELALOUF O. and CHANDRAN V.,Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline?,Current Rheumatology Reports,2018年,20:36,Page.1-8

Also Published As

Publication number Publication date
WO2020247371A8 (en) 2021-12-02
JP2022535550A (ja) 2022-08-09
EP3980463A4 (en) 2023-06-28
US20220396632A1 (en) 2022-12-15
KR20220042055A (ko) 2022-04-04
BR112021024242A2 (pt) 2022-04-26
TW202110891A (zh) 2021-03-16
JP2025129213A (ja) 2025-09-04
CA3141334A1 (en) 2020-12-10
AU2020288823A1 (en) 2022-02-03
US12552873B2 (en) 2026-02-17
IL288510A (en) 2022-01-01
CN114401990A (zh) 2022-04-26
EP3980463A1 (en) 2022-04-13
WO2020247371A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
US12552873B2 (en) Anti-PSGL-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
US20220396627A1 (en) Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
US20230348603A1 (en) Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
CA2959821C (en) Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA
US20220251233A1 (en) Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
US20220363752A1 (en) Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
JP2026507507A (ja) Ccr9陽性癌を治療するccr9標的化部分
WO2026064353A1 (en) Diagnostics and therapeutics targeting slc13a3
HK40126807A (en) Cnx antigen-binding molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230602

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250520

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250625

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250722

R150 Certificate of patent or registration of utility model

Ref document number: 7716992

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150